Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.
Inclusion Criteria
- Histologically or cytologically confirmed diagnosis of metastatic or locally advanced HR+/HER2- breast cancer
- Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must be willing to continue for the duration of the study.
- Negative pregnancy test for females of childbearing potential. Female subjects who are not surgically sterile must use a medically effective contraceptive method from screening until 2 years after the last dose of study treatment.
- Progression of disease during or within 12 months of completing (neo)adjuvant endocrine therapy (ET) or progression of disease after 12 months of completing (neo)adjuvant ET.
- Adequate archival, fresh tumor tissue, or liquid biopsy for the analysis of PIK3CA mutational status.
- Permitted prior therapies:
- (neo)adjuvant fulvestrant only if the treatment duration < 6 months
- (neo)adjuvant chemotherapy
- (neo)adjuvant CDK4/6 inhibitor, unless PD was on or within 6 months of discontinuation of CDK4/6i i. Study 1: if disease progression was on or within event occurred >6 months of discontinuation after completion of CDK4/6 inhibitor portion of treatment. ii. Study 2: if disease progression event occurred >12 months after completion of CDK4/6 inhibitor portion of treatment.
- Subject has radiologically measurable disease according to RECIST v1.1, per local assessment. Patients with nonmeasurable bone-only disease are not eligible. Patients with bone-only disease that has lytic or mixed lytic/blastic lesions and at least one measurable soft tissue component per RECIST v1.1 may be eligible.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Life expectancy of at least >6 months.
- Adequate bone marrow, hepatic, renal and coagulation function.
Exclusion Criteria
- Concurrent malignancies other than adequately treated non-melanoma skin cancer. Previous malignancies in remission but curatively treated with no evidence of disease progression and judged by local Investigator to be at low risk of impacting health or survival while on study.
- Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor, a protein kinase B (Akt) inhibitor, or a mechanistic target of rapamycin (mTOR) inhibitor or any other selective estrogen receptor degrader (SERD), except fulvestrant, used in (neo)adjuvant setting.
- Prior treatment with systemic anticancer therapy for ABC
- Subjects with type 1 diabetes, or uncontrolled type 2 diabetes requiring daily insulin therapy.
- Known and untreated, or active, brain or leptomeningeal metastases
- History of clinically significant cardiovascular abnormalities
- Known, clinically significant ophthalmic conditions
- History of drug-induced symptomatic interstitial lung disease (pneumonitis) or hepatitis
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06757634.
Locations matching your search criteria
United States
California
Los Angeles
Kansas
Kansas City
Missouri
Saint Louis
Ohio
Columbus
Texas
Houston
San Antonio
Washington
Seattle
This is a Phase 3, open-label, randomized clinical trial evaluating the efficacy and
safety of gedatolisib plus endocrine therapy and palbociclib versus endocrine therapy and
ribociclib for the treatment of patients with advanced (inoperable) or metastatic hormone
receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) breast
cancer. Following completion of the screening procedures to determine eligibility,
patients will be assigned manually according to their endocrine sensitivity status to
either Study 1 (endocrine-resistant) or Study 2 (endocrine-sensitive) and subsequently be
randomized 1:1 to either investigational treatment or standard-of-care control.
Study 1 is expected to enroll approximately 440 subjects with treatment-naïve
endocrine-resistant ABC whose cancer progressed while receiving or within 12 months of
completing adjuvant endocrine therapy. The trial will evaluate the efficacy and safety of
the investigational arm (gedatolisib combined with palbociclib and fulvestrant - Arm A)
compared to the control arm (ribociclib combined with fulvestrant - Arm B).
Study 2 is expected to enroll approximately 740 subjects with treatment-naïve
endocrine-sensitive ABC whose cancer relapsed or progressed 12 months or more after
completion of adjuvant endocrine therapy, or those with de novo metastatic disease
without prior endocrine therapy exposure. The trial will evaluate the efficacy and safety
of the investigational arm (gedatolisib combined with palbociclib and letrozole - Arm C)
compared to the control arm (ribociclib combined with letrozole - Arm D).
Gedatolisib is an intravenously administered pan-PI3K/mTOR inhibitor. Palbociclib and
ribociclib are CDK4/6 inhibitors. Fulvestrant is a selective estrogen receptor degrader
(SERD). Letrozole is an aromatase inhibitor (AI).
Trial PhasePhase III
Trial Typetreatment
Lead OrganizationCelcuity Inc
- Primary IDCELC-G-302
- Secondary IDsNCI-2025-04135
- ClinicalTrials.gov IDNCT06757634